Regarding gastrointestinal primary tumours, median survival was 0.9 versus 3.3 months; P = 0.215. For melanoma patients, these figures were Axitinib 1.1 versus 5.5 months; P = 0.02.Figure 1Kaplan-Meier curves for overall survival: normal LDH (n = 41) versus elevated LDH (n = 59); P = 0.037.Figure 2Kaplan-Meier curves for overall survival: LDH less than 1.5x upper limit of normal (n = 65) versus LDH higher than 1.5x upper limit of normal (n = 35); P = 0.013.Figure 3Kaplan-Meier curves for overall survival: LDH highest quartile (n = 25) versus LDH lowest quartile (n = 25) versus intermediate (n = 50); P = 0.017.Data on LDH kinetics were available in 33 patients. We compared the LDH level 2 months before WBRT to that immediately before WBRT. In 20 cases, an increase of at least 10% during the 2 months time period was found.
In the remaining 13 cases LDH had been stable, slightly decreasing or increasing <10%. Patients with LDH increase ��10% had significantly shorter Temsirolimus FDA survival (median 2.3 months) as compared to the remaining patients (median 13.5 months); P = 0.001 (Figure 4).Figure 4Kaplan-Meier curves for overall survival: LDH increase ��10% within 2 months (n = 20) selleck chemical versus no such increase (n = 13); P = 0.001.3.2. Multivariate AnalysesAll Cox regression analyses included KPS (continuous variable), age (continuous variable), number of brain metastases detected on magnetic resonance imaging scans (continuous variable), and presence versus absence of extracranial metastases, that is, all parameters that determine the GPA classification. When adding LDH (continuous variable) to these 4 parameters, only KPS (P = 0.0001) and LDH (P = 0.002) retained statistical significance.